• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal and Metabolic Medicine
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality Assessment
      • Environmental, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • People and Culture
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
Novartis shares neuroscience story at SfN’s 44th Annual Meeting
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/Discovery

Novartis shares neuroscience story at SfN’s 44th Annual Meeting

Induced pluripotent stem cells offer neuroscientist at NIBR a way to study autism. Learn how a brain-in-a-dish is created for drug discovery.

Nov 14, 2014

Know any good neuroscience jokes? How about this one: What is a sleeping brain’s favorite rock band? ...REM.

Laughing? Under the hashtag #NeuroHumor, the Novartis Institutes for BioMedical Research (NIBR) plans to share clever neuroscience jokes on Twitter at the Society for Neuroscience’s 44th Annual Meeting in Washington, D.C., November 15 to 19. With more than 30,000 attendees, the meeting marks a great spot for us to engage the global neuroscience community.

Beyond telling jokes, we’re telling our neuroscience story--and it’s an important one. NIBR resurrected its neuroscience research under the leadership of Ricardo Dolmetsch in 2013. His group seeks therapies for some of the toughest neurological diseases. Their use of induced pluripotent stem (iPS) cell technology to study these diseases, including autism, inspired the “Sketching Science” video below.

 

By following @NovartisScience on Twitter, you’ll see all of our meeting-related tweets (hashtag #sfn14) and NIBR features. Look for a story about how our collaboration with ChemPartner is leading to a potential strategy for treating narcolepsy. And Dr. Botond Roska of the Novartis-affiliated Friedrich Miescher Institute for BioMedical Research (FMI) will deliver a Presidential Special Lecture at the meeting.

We’ll ask once again. Know any good neuroscience jokes? If so, please share them on Twitter with the #NeuroHumor hashtag.

Media Inquiries: Jeff Lockwood +1 617 871 7026

Tags: 
Novartis Institutes for BioMedical Research
    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

RNA strand
Discovery

Take a visual tour of medicines that target RNA

A kidney patient is smiling at the camera
Discovery

New hope for treating inflammatory diseases of the kidney

2D rendering of kidneys
Discovery

Predictive analytics could bring medicines to patients faster

You are here

  1. Home ›
  2. Stories ›
  3. Discovery

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.